BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E, Torres M. Diagnosis for Latent Tuberculosis Infection: New Alternatives. Front Immunol 2020;11:2006. [PMID: 33013856 DOI: 10.3389/fimmu.2020.02006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Alvarez AH. Revisiting tuberculosis screening: An insight to complementary diagnosis and prospective molecular approaches for the recognition of the dormant TB infection in human and cattle hosts. Microbiol Res 2021;252:126853. [PMID: 34536677 DOI: 10.1016/j.micres.2021.126853] [Reference Citation Analysis]
2 Luo Y, Xue Y, Mao L, Lin Q, Tang G, Song H, Liu W, Tong S, Hou H, Huang M, Ouyang R, Wang F, Sun Z. Activation Phenotype of Mycobacterium tuberculosis-Specific CD4+ T Cells Promoting the Discrimination Between Active Tuberculosis and Latent Tuberculosis Infection. Front Immunol 2021;12:721013. [PMID: 34512645 DOI: 10.3389/fimmu.2021.721013] [Reference Citation Analysis]
3 Egorova A, Salina EG, Makarov V. Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review). Int J Mol Sci 2021;22:13317. [PMID: 34948114 DOI: 10.3390/ijms222413317] [Reference Citation Analysis]
4 Joshi H, Kandari D, Bhatnagar R. Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications. Virulence 2021;12:2721-49. [PMID: 34637683 DOI: 10.1080/21505594.2021.1990660] [Reference Citation Analysis]
5 Delemarre EM, van Hoorn L, Bossink AWJ, Drylewicz J, Joosten SA, Ottenhoff THM, Akkerman OW, Goletti D, Petruccioli E, Navarra A, van den Broek BTA, Paardekooper SPA, van Haeften I, Koenderman L, Lammers JJ, Thijsen SFT, Hofland RW, Nierkens S. Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis. Front Immunol 2021;12:725447. [PMID: 34691031 DOI: 10.3389/fimmu.2021.725447] [Reference Citation Analysis]
6 Ahn SS, Kim HW, Park Y. Frequency and Factors of Indeterminate QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold PLUS Test Results in Rheumatic Diseases. J Clin Med 2021;10:4357. [PMID: 34640376 DOI: 10.3390/jcm10194357] [Reference Citation Analysis]
7 Mustafa AS. Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins. Vaccines (Basel) 2021;9:27. [PMID: 33430286 DOI: 10.3390/vaccines9010027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 El-Sheikh N, Mousa NO, Osman A, Tawfeik AM, Taha BA, Mahran H, Saleh AM, El-Shiekh I, Amin W, Elrefaei M. Assessment of Interferon Gamma-Induced Protein 10 mRNA Release Assay for Detection of Latent Tuberculosis Infection in Egyptian Pediatric Household Contacts. Int J Infect Dis 2021;109:223-9. [PMID: 34271200 DOI: 10.1016/j.ijid.2021.07.024] [Reference Citation Analysis]
9 Roussel L, Brindel A, Pouget C, Treffel G, Billon Y, Vaillant P, Tiotiu A. Pleural Effusion Occurring During Lung Cancer Immunotherapy: A Challenge for the Clinician. Arch Bronconeumol 2021:S0300-2896(21)00177-0. [PMID: 34167858 DOI: 10.1016/j.arbres.2021.05.021] [Reference Citation Analysis]
10 Tang J, Huang Y, Cai Z, Ma Y. Mycobacterial heparin-binding hemagglutinin (HBHA)-induced interferon-γ release assay (IGRA) for discrimination of latent and active tuberculosis: A systematic review and meta-analysis. PLoS One 2021;16:e0254571. [PMID: 34270559 DOI: 10.1371/journal.pone.0254571] [Reference Citation Analysis]
11 Chadalawada S, Kathirvel K, Lalitha P, Rathinam SR, Devarajan B. Dysregulated expression of microRNAs in aqueous humor from intraocular tuberculosis patients. Mol Biol Rep 2021. [PMID: 34677715 DOI: 10.1007/s11033-021-06846-4] [Reference Citation Analysis]
12 Fukushima K, Akagi K, Kondo A, Kubo T, Sakamoto N, Mukae H. First clinical evaluation of the QIAreachTM QuantiFERON-TB for tuberculosis infection and active pulmonary disease. Pulmonology 2021:S2531-0437(21)00151-3. [PMID: 34362702 DOI: 10.1016/j.pulmoe.2021.07.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Fukushima K, Kubo T, Akagi K, Miyashita R, Kondo A, Ehara N, Takazono T, Sakamoto N, Mukae H. Clinical evaluation of QuantiFERON®-TB Gold Plus directly compared with QuantiFERON®-TB Gold In-Tube and T-Spot®.TB for active pulmonary tuberculosis in the elderly. J Infect Chemother 2021;27:1716-22. [PMID: 34412981 DOI: 10.1016/j.jiac.2021.08.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Luo Y, Xue Y, Tang G, Lin Q, Song H, Liu W, Yin B, Huang J, Wei W, Mao L, Wang F, Sun Z. Combination of HLA-DR on Mycobacterium tuberculosis-Specific Cells and Tuberculosis Antigen/Phytohemagglutinin Ratio for Discriminating Active Tuberculosis From Latent Tuberculosis Infection. Front Immunol 2021;12:761209. [PMID: 34858413 DOI: 10.3389/fimmu.2021.761209] [Reference Citation Analysis]